The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
|Articles|January 19, 2022
Daily Medication Pearl: Brimonidine Ophthalmic Solution (Alphagan P)
Author(s)Saro Arakelians, PharmD
Brimonidine ophthalmic solution (Alphagan P) is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Advertisement
Medication Pearl of the Day: Brimonidine ophthalmic solution (Alphagan P)
Indication: Brimonidine ophthalmic solution (Alphagan P) is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Insight:
- Dosing: One drop in the affected eye(s), 3 times daily, approximately 8 hours apart.
- Dosage forms: Solution containing 1 or 1.5 mg/mL brimonidine tartrate.
- Adverse events: Most common adverse reactions occurring in approximately 5% to 20% of patients receiving brimonidine ophthalmic solution (0.1%-0.2%) included allergic conjunctivitis, burning sensation, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.
- Mechanism of action: Alphagan P is a relatively selective alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at 2 hours post-dosing.
- Manufacturer: Allergan
Sources:
Advertisement
Related to this article
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
5